Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.50 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 2/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SNCA | P37840 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL279251 | 1.00 | PPARG (0.50) | PPARGMDM4TP53MDM2RXRA | |
| SCHEMBL275409 | 1.00 | PPARG (0.50) | PPARGMDM4TP53MDM2RXRA | |
| SCHEMBL275608 | 0.93 | PPARG (0.45) | PPARGMDM4TP53MDM2RXRA | |
| SCHEMBL275607 | 0.93 | PPARG (0.45) | PPARGMDM4TP53MDM2RXRA | |
| SCHEMBL279165 | 0.93 | PPARG (0.45) | PPARGMDM4TP53MDM2RXRA | |
| SCHEMBL27740826 | 0.92 | PPARG (0.48) | PPARGMDM4TP53MDM2RXRA | |
| SCHEMBL274462 | 0.92 | MDM4 (0.43) | PPARGMDM4TP53MDM2APP | |
| SCHEMBL277025 | 0.92 | MDM4 (0.43) | PPARGMDM4TP53MDM2APP | |
| SCHEMBL274463 | 0.92 | MDM4 (0.43) | PPARGMDM4TP53MDM2APP | |
| SCHEMBL13929141 | 0.88 | MDM4 (0.41) | PPARGMDM4TP53MDM2APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134001-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-03-13 | — | — | US | disclosed |
| EP-2229396-B1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-10 | — | — | EP | disclosed |
| EP-2229396-A1 | SPIROINDOLINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009077357-A1 | SPIROINDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| US-20090156610-A1 | Spiroindolinone Derivatives | DING QINGJIE | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156610-A1 | Spiroindolinone Derivatives | SDHA, AR, XPOT | PPARG 460/4885MDM4 3506/4885TP53 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.